Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
出版年份 2018 全文链接
标题
Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
作者
关键词
-
出版物
POSTGRADUATE MEDICINE
Volume -, Issue -, Pages 1-12
出版商
Informa UK Limited
发表日期
2018-11-20
DOI
10.1080/00325481.2019.1549459
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2017) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
- (2017) George Grunberger et al. Diabetes Therapy
- Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
- (2017) George Grunberger et al. Diabetes Therapy
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
- (2016) David Cherney et al. DIABETOLOGIA
- Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
- (2016) Maryam Afkarian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
- (2016) Matthew R. Weir POSTGRADUATE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
- (2014) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now